Thread by @SpichakSimon

There's a press release for a new Alzheimer's drug from @EliLillyandCo. My editor @alexmarvar
and I didn't think new coverage did a fair job explaining the results. Here's the jargon free version explaining the #donanemab results from @Being_Patient_

beingpatient.com/eli-lilly-dona…

And of course shout out to @schrag_matthew for back-of-the-napkin calculations of some of the raw CDR-SB scores.

The gist of it all:

Also for the love of all that is science - we need to start explaining results of studies in terms of what the outcomes mean for PATIENTS rather than X% change, which can be misleading.